BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 33003326)

  • 1. Differential Regulation of Telomeric Complex by
    Deregowska A; Pepek M; Pruszczyk K; Machnicki MM; Wnuk M; Stoklosa T
    Genes (Basel); 2020 Sep; 11(10):. PubMed ID: 33003326
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The interplay between telomeric complex members and BCR::ABL1 oncogenic tyrosine kinase in the maintenance of telomere length in chronic myeloid leukemia.
    Deręgowska A; Pępek M; Solarska I; Machnicki MM; Pruszczyk K; Dudziński M; Niesiobędzka-Krężel J; Seferyńska I; Sawicki W; Wnuk M; Stokłosa T
    J Cancer Res Clin Oncol; 2023 Aug; 149(10):7103-7112. PubMed ID: 36871092
    [TBL] [Abstract][Full Text] [Related]  

  • 3. miR-96 acts as a tumor suppressor via targeting the BCR-ABL1 oncogene in chronic myeloid leukemia blastic transformation.
    Huang T; Fu Y; Wang S; Xu M; Yin X; Zhou M; Wang X; Chen C
    Biomed Pharmacother; 2019 Nov; 119():109413. PubMed ID: 31518872
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BCR-ABL1 mediated miR-150 downregulation through MYC contributed to myeloid differentiation block and drug resistance in chronic myeloid leukemia.
    Srutova K; Curik N; Burda P; Savvulidi F; Silvestri G; Trotta R; Klamova H; Pecherkova P; Sovova Z; Koblihova J; Stopka T; Perrotti D; Polakova KM
    Haematologica; 2018 Dec; 103(12):2016-2025. PubMed ID: 30049824
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular biology of bcr-abl1-positive chronic myeloid leukemia.
    Quintás-Cardama A; Cortes J
    Blood; 2009 Feb; 113(8):1619-30. PubMed ID: 18827185
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RAG enhances BCR-ABL1-positive leukemic cell growth through its endonuclease activity in vitro and in vivo.
    Yuan M; Wang Y; Qin M; Zhao X; Chen X; Li D; Miao Y; Otieno Odhiambo W; Liu H; Ma Y; Ji Y
    Cancer Sci; 2021 Jul; 112(7):2679-2691. PubMed ID: 33949040
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants.
    Soverini S; De Benedittis C; Castagnetti F; Gugliotta G; Mancini M; Bavaro L; Machova Polakova K; Linhartova J; Iurlo A; Russo D; Pane F; Saglio G; Rosti G; Cavo M; Baccarani M; Martinelli G
    BMC Cancer; 2016 Aug; 16():572. PubMed ID: 27485109
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Decreased microRNA-30a levels are associated with enhanced ABL1 and BCR-ABL1 expression in chronic myeloid leukemia.
    Liu Y; Song Y; Ma W; Zheng W; Yin H
    Leuk Res; 2013 Mar; 37(3):349-56. PubMed ID: 23287430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression and activity of Fyn mediate proliferation and blastic features of chronic myelogenous leukemia.
    Singh MM; Howard A; Irwin ME; Gao Y; Lu X; Multani A; Chandra J
    PLoS One; 2012; 7(12):e51611. PubMed ID: 23284724
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heterogeneous BCR-ABL1 signal patterns identified by fluorescence in situ hybridization are associated with leukemic clonal evolution and poorer prognosis in BCR-ABL1 positive leukemia.
    Zhang Z; Chen Z; Jiang M; Liu S; Guo Y; Wan L; Li F
    BMC Cancer; 2019 Oct; 19(1):935. PubMed ID: 31594548
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Next-generation sequencing for BCR-ABL1 kinase domain mutation testing in patients with chronic myeloid leukemia: a position paper.
    Soverini S; Abruzzese E; Bocchia M; Bonifacio M; Galimberti S; Gozzini A; Iurlo A; Luciano L; Pregno P; Rosti G; Saglio G; Stagno F; Tiribelli M; Vigneri P; Barosi G; Breccia M
    J Hematol Oncol; 2019 Dec; 12(1):131. PubMed ID: 31801582
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular pathogenesis of Philadelphia-positive chronic myeloid leukemia - is it all BCR-ABL?
    Rumpold H; Webersinke G
    Curr Cancer Drug Targets; 2011 Jan; 11(1):3-19. PubMed ID: 21062244
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of BCR-ABL1 kinase domain mutations causing imatinib resistance in chronic myelogenous leukemia.
    Moore FR; Yang F; Press RD
    Methods Mol Biol; 2013; 999():25-39. PubMed ID: 23666688
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of 46 patient-specific BCR-ABL1 fusions and detection of SNPs upstream and downstream the breakpoints in chronic myeloid leukemia using next generation sequencing.
    Linhartova J; Hovorkova L; Soverini S; Benesova A; Jaruskova M; Klamova H; Zuna J; Machova Polakova K
    Mol Cancer; 2015 Apr; 14():89. PubMed ID: 25928096
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clonal distribution of BCR-ABL1 mutations and splice isoforms by single-molecule long-read RNA sequencing.
    Cavelier L; Ameur A; Häggqvist S; Höijer I; Cahill N; Olsson-Strömberg U; Hermanson M
    BMC Cancer; 2015 Feb; 15():45. PubMed ID: 25880391
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Deciphering Potential Molecular Signatures to Differentiate Acute Myeloid Leukemia (AML) with
    Boucher L; Sorel N; Desterke C; Chollet M; Rozalska L; Gallego Hernanz MP; Cayssials E; Raimbault A; Bennaceur-Griscelli A; Turhan AG; Chomel JC
    Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37895120
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene expression analysis of BCR/ABL1-dependent transcriptional response reveals enrichment for genes involved in negative feedback regulation.
    Håkansson P; Nilsson B; Andersson A; Lassen C; Gullberg U; Fioretos T
    Genes Chromosomes Cancer; 2008 Apr; 47(4):267-75. PubMed ID: 18181176
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Telomere loss is accompanied by decreased pool of shelterin proteins TRF2 and RAP1, elevated levels of TERRA and enhanced glycolysis in imatinib-resistant CML cells.
    Deregowska A; Lewinska A; Warzybok A; Stoklosa T; Wnuk M
    Toxicol In Vitro; 2023 Aug; 90():105608. PubMed ID: 37149272
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytogenetic, fluorescence in situ hybridization, and genomic array characterization of chronic myeloid leukemia with cryptic BCR-ABL1 fusions.
    Shao L; Miller S; Keller-Ramey J; Zhang Y; Roulston D
    Cancer Genet; 2015; 208(7-8):396-403. PubMed ID: 26186983
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MXD1 regulates the imatinib resistance of chronic myeloid leukemia cells by repressing BCR-ABL1 expression.
    Huan C; Jin L; Heng W; Na A; Yuming P; Xin D; Qiaoxia Z
    Leuk Res; 2018 Dec; 75():1-6. PubMed ID: 30419548
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.